Series J, Number 54
Family Planning Programs

CONTENTS

Home (Key Points)

Bleeding Changes Affect Contraceptive Choice and Use

Counseling and Treatment Can Help

Box: Contraception and Bleeding Changes: What Are the Facts?

Box: Would More Women Use a Family Planning Method That Stops Monthly Bleeding?

What Shapes Women's Attitudes About Bleeding Changes?

Box: Better Understanding Menstruation Helps Girls and Women
Web Table 1. Knowledge of Fertile Time is Poor Among Women and Men of Reproductive Age

Spotlight: Nepal's A GIFT for RH Project Teaches Girls, Changes Attitudes

Bibliography

Coming Soon: Family Planning: A Global Handbook for Providers

Credits

• Provider Guide: Managing Bleeding Changes Caused by Contraceptive Methods
• Counseling Aid: Typical Bleeding Patterns With Selected Contraceptive Methods

• Table: Discontinuation of Contraceptive Methods Due to Bleeding Changes Varies in Clinical Trials
• Box: Hormonal Contraception Relieves Some Reproductive Conditions

Order this report
Download PDF or PowerPoint
E-mail this page
See companion INFO Reports, "Key Facts About the Menstrual Cycle"
See more Population Reports

Bibliography

The links included in this bibliography were up-to-date as of publication.

1. ABIOYE-KUTEYI, E.A. Menstrual knowledge and practices amongst secondary school girls in Ile Ife, Nigeria. Journal of the Royal Society of Health 120(1): 23–26. Mar. 2000.

2. ADETUNJI, B., BASIL, B., MATHEWS, M., WILLIAMS, A., and OSINOWO, T. Methodological issues in a study of long-term maintenance therapy with quetiapine versus haloperidol decanoate. Journal of Clinical Psychiatry 67(3): 497 (author reply 497–498). Mar. 2006.

3. ADHIKARI, K.P., MABUHANG, B.K., and KUNWAR, L.S. Feasibility study of monthly combined injectable contraception in Nepal. Kathmandu, Nepal, Centre for Population Research and Training, Tribhuvan University, Kirtipur, Jan. 2004. 58 p.

4. AKTUN, H., MOROY, P., CAKMAK, P., YALCUN, H.R., and MOLLAMAHMUTOGLU, L. Depo-Provera: Use of a long-acting progestin injectable contraceptive in Turkish women. Contraception 72(1): 24–27. Jul. 2005.

5. AL-SABIR, A., BHADRA, S.K., SULTANA, S., and BINTE ALI, A. Hygiene practices during menstruation: Women's beliefs and restrictions. Dhaka, Bangladesh, National Institute of Population Research and Training, Jul. 1998. 42 p.

6. ALBERS, J.R., HULL, S.K., and WESLEY, R.M. Abnormal uterine bleeding. American Family Physician 69(8): 1915–1926. Apr. 15, 2004.

7. ANAND, R. (Abt Associates) [Creative ways to explain bleeding changes caused by contraceptives to family planning clients] Personal communication, Jun. 27, 2006.

8. ANDERSSON, J.K. and RYBO, G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. British Journal of Obstetrics and Gynaecology 97(8): 690–694. Aug. 1990.

9. ANDERSSON, K., ODLIND, V., and RYBO, G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: A randomized comparative trial. Contraception 49(1): 56–72. Jan. 1994.

10. ANDRIST, L.C., ARIAS, R.D., NUCATOLA, D., KAUNITZ, A.M., MUSSELMAN, B.L., REITER, S., BOULANGER, J., DOMINGUEZ, L., and EMMERT, S. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 70(5): 359–363. Nov. 2004.

11. ASKEW, I., CHEGE, J., NJUE, C., and RADENY, S. A multi-sectoral approach to providing reproductive health information and services to young people in Western Kenya: Kenya adolescent reproductive health project. Washington, DC, Population Council, Jun. 2004. (FRONTIERS Final Report) 43 p. (Available: http://www.popcouncil.org/pdfs/frontiers/FR_FinalReports/Kenya_KARP%20Adol.pdf)

12. BA, M.G., MOREAU, J.C., SOKAL, D., DUNSON, R., DAO, B., KOUEDOU, D., and DIADHIOU, F. A 5-year clinical evaluation of Norplant implants in Senegal. Contraception 59(6): 377–381. Jun. 1999.

13. BACKMAN, T., HUHTALA, S., LUOTO, R., TUOMINEN, J., RAURAMO, I., and KOSKENVUO, M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstetrics and Gynecology 99(4): 608—613. Apr. 2002.

14. BANGLADESH CENTER FOR COMMUNICATION PROGRAMS (BCCP) and HEALTH COMMUNICATION PARTNERSHIP (HCP). The Circus Girl. Nijeke Jano [Know yourself]. Bangladesh, BCCP and HCP, 2004. 50 p.

15. BASSOL, S., CRAVIOTO, M.C., DURAND, M., BAILON, R., CARRANZA, S., FUGAROLAS, J., GAONA, R., PARADA, L.M., CELIS, C., SANTOYO, S., GARZA-FLORES, J., VAZQUEZ, L., LOPEZ, C., GURUCHARRI, C., NOVELLI, J., CARNEIRO DE OLIVEIRA, H., MENDEZ, J., DE ANDRADE, M.E., DE MELLO, N.R., DE MELO, K., CHADA, E., YASSLE, M.E., CASTANEDA, A., GOMEZ, P., ARBOLEDA, C., TRUJILLO, L., BUCHELI, R., HIDALGO, I., OLAVIDE, R., PAREJARIOS, J., SUCCAR, J., REYES-MARQUEZ, R., and ALBRECHT, G. Mesigyna once-a-month combined injectable contraceptive: Experience in Latin America. Contraception 61(5): 309–316. May 2000.

16. BHATT, R. and BHATT, M. Perceptions of Indian women regarding menstruation. International Journal of Gynecology and Obstetrics 88(2): 164–167. Feb. 2005.

17. BRANDES, J.L. The influence of estrogen on migraine: A systematic review. Journal of the American Medical Association 295(15): 1824–1830. Apr. 19, 2006.

18. BROWN, S., VESSEY, M., and STRATTON, I. The influence of method of contraception and cigarette smoking on menstrual patterns. British Journal of Obstetrics and Gynaecology 95(9): 905–910. Sep. 1988.

19. BULUT, A., FILIPPI, V., MARSHALL, T., NALBANT, H., YOLSAL, N., and GRAHAM, W. Contraceptive choice and reproductive morbidity in Istanbul. Studies in Family Planning 28(1): 35–43. Mar. 1997.

20. BURKMAN, R.T., JR. The role of oral contraceptives in the treatment of hyperandrogenic disorders. American Journal of Medicine 98(1A): 130S–136S. Jan. 1995.

21. CANTO DE CETINA, T.E., CANTO, P., and ORDONEZ LUNA, M. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. Contraception 63(3): 143–146. Mar. 2001.

22. CARLBORG, L. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version. Contraception 27(5): 439–452. May 1983.

23. CASTLE, S. Factors influencing young Malians' reluctance to use hormonal contraceptives. Studies in Family Planning 34(3): 186–199. Sep. 2003.

24. CASTLE, S., KONATÉ, M.K., ULIN, P.R., and MARTIN, S. Clandestine contraceptive use in urban Mali. Studies in Family Planning 30(3): 231–248. Sep. 1999.

25. CENTRE FOR DEVELOPMENT AND POPULATION ACTIVITIES (CEDPA). A GIFT for RH project, Nepal: Endline evaluation. Kathmandu, Nepal, CEDPA Nepal Country Office, Sep. 2002. 32 p.

26. CENTRE FOR DEVELOPMENT AND POPULATION ACTIVITIES (CEDPA). Adolescent girls initiate for their reproductive health (Phase II). An endline survey in Baglung and Lalitpur districts. Kathmandu, Nepal, CEDPA, Nepal Country Office, 2004. 69 p. (Available: http://www.cedpa.org/content/publication/detail/658)

27. CENTRE FOR DEVELOPMENT AND POPULATION ACTIVITIES (CEDPA). Building reproductive health awareness among adolescent girls in conflict affected districts of Nepal. Washington, DC, CEDPA, Jun. 2006. 21 p.

28. CHAMBERLAIN, G. and FOULKES, J. Long-term effects of laparoscopic sterilization on menstruation. Southern Medical Journal 69(11): 1474–1475. Nov. 1976.

29. CHAN, W.Y., DAWOOD, M.Y., and FUCHS, F. Prostaglandins in primary dysmenorrhea: Comparison of prophylactic and nonprophylactic treatment with ibuprofen and use of oral contraceptives. American Journal of Medicine 70(3): 535–541. Mar. 1981.

30. COUTINHO, E.M., SPINOLA, P., TOMAZ, G., MORAIS, K., NASSAR DE SOUZA, R., SABINO PINHO NETO, J., DE BARROS LEAL, W., BOMFIM HIPPOLITO, S., and D'AUREA ABRANCHES, A. Efficacy, acceptability, and clinical effects of a low-dose injectable contraceptive combination of dihydroxyprogesterone acetophenide and estradiol enanthate. Contraception 61(4): 277–280. Apr. 2000.

31. CROSIGNANI, P.G., VERCELLINI, P., MOSCONI, P., OLDANI, S., CORTESI, I., and DE GIORGI, O. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstetrics and Gynecology 90(2): 257–263. Aug. 1997.

32. CUONG, D.T. and MY HUONG, N.T. Comparative phase III clinical trial of two injectable contraceptive preparations, depot-medroxyprogesterone acetate and Cyclofem, in Vietnamese women. Contraception 54(3): 169–179. Sep. 1996.

33. D'SOUZA, R.E. and GUILLEBAUD, J. Risks and benefits of oral contraceptive pills. Best Practice and Research. Clinical Obstetrics and Gynaecology 16(2): 133–154. Apr. 2002.

34. DANLI, S., QINGXIANG, S., and GUOWEI, S. A multicentered clinical trial of the long-acting injectable contraceptive Depo Provera in Chinese women. Contraception 62(1): 15–18. Jul. 2000.

35. DATEY, S., GAUR, L.N., and SAXENA, B.N. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)—an Indian experience. An ICMR Task Force Study. Contraception 51(3): 155–165. Mar. 1995.

36. DAVIS, A., GODWIN, A., LIPPMAN, J., OLSON, W., and KAFRISSEN, M. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstetrics and Gynecology 96(6): 913–920. 2000.

37. DHAMI, S. and SHEIKH, A. The Muslim family: Predicament and promise. Western Journal of Medicine 173(5): 352–356. Nov. 2000.

38. DUNSON, T.R., MCLAURIN, V.L., AGUAYO, E.L., DE SILVA, P., CALVENTI, V., GERAIS, A.S., and SERANI, R.G. A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives. Contraception 47(6): 515–525. Jun. 1993.

39. DUNSON, T.R., MCLAURIN, V.L., GRUBB, G.S., and ROSMAN, A.W. A multicenter clinical trial of a progestin-only oral contraceptive in lactating women. Contraception 47(1): 23–35. Jan. 1993.

40. DUNSON, T.R., MCLAURIN, V.L., ISRANGKURA, B., LEELAPATTANA, B., MUKHERJEE, R., PEREZ-PALACIOS, G., and SALEH, A.A. A comparative study of two low-dose combined oral contraceptives: Results from a multicenter trial. Contraception 48(2): 109–119. Aug. 1993.

41. EDELMAN, A., GALLO, M., JENSEN, J., NICHOLS, M., SCHULZ, K., and GRIMES, D.A. Continuous or extended cycle versus cyclic use of combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD004695.

42. EL-GILANY, A.H., BADAWI, K., and EL-FEDAWY, S. Menstrual hygiene among adolescent schoolgirls in Mansoura, Egypt. Reproductive Health Matters 13(26): 147–152. Nov. 2005.

43. ESTANISLAU DO AMARAL, M.C., HARDY, E., HEBLING, E.M., and FAUNDES, A. Menstruation and amenorrhea: Opinion of Brazilian women. Contraception 72(2): 157–161. Aug. 2005.

44. FACULTY OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE (FFPRHC). FFPRHC guidance: Contraception for women aged over 40 years. Journal of Family Planning and Reproductive Health Care 31(1): 51–64. Jan. 2005.

45. FAGUER, C. Study and significance of ferritin levels in 104 women using intrauterine devices. Journal de Gynécologie, Obstétrique et Biologie de la Reproduction 23(2): 141–144. 1994.

46. FAKEYE, O. and ADEGOKE, A. The characteristics of the menstrual cycle in Nigerian schoolgirls and the implications for school health programmes. African Journal of Medicine and Medical Sciences 23(1): 13–17. Mar. 1994.

47. FARR, G. and AMATYA, R. Contraceptive efficacy of the Copper T 380A and Copper T 200 intrauterine devices: Results from a comparative clinical trial in six developing countries. Contraception 49(3): 231–243. Mar. 1994.

48. FARR, G., AMATYA, R., ACOSTA, M., EKWEMPU, C., and KISNINCI, H. Clinical performance of the TCu 380A and Lippes Loop IUDs in three developing countries. Contraception 52(1): 17–22. Jul. 1995.

49. FARR, G., AMATYA, R., DOH, A., EKWEMPU, C.C., TOPPOZADA, M., and RUMINJO, J. An evaluation of the Copper-T 380A IUD's safety and efficacy at three African centers. Contraception 53(5): 293–298. May 1996.

50. FAÚNDES, A., ALVAREZ, F., BRACHE, V., and TEJADA, A.S. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. International Journal of Gynecology and Obstetrics 26(3): 429–433. Jun. 1988.

51. FINLEY, H. Lakshmi Murthy: Teaching girls about puberty, menstruation and how to make washable menstrual pads, in rural India. (http://www.mum.org/indiapad.htm). Jul. 25, 2006

52. FRASER, I.S., WEISBERG, E., MINEHAN, E., and JOHANSSON, E.D. A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings. Contraception 61(4): 241–251. Apr. 2000.

53. FRASSINELLI-GUNDERSON, E.P., MARGEN, S., and BROWN, J.R. Iron stores in users of oral contraceptive agents. American Journal of Clinical Nutrition 41(4): 703–712. Apr. 1985.

54. FUTURES GROUP INTERNATIONAL. End of project report: Jamaica adolesecent reproductive health activity. Washington, DC, Futures Group International, Jan. 2005. 50 p.

55. GARG, S., SHARMA, N., and SAHAY, R. Socio-cultural aspects of menstruation in an urban slum in Delhi, India. Reproductive Health Matters 9(17): 16–25. May 2001

56. GARZA-FLORES, J., MORAKS DEL OLMO, A., FUZIWARA, J.L., FIGUEROA, J.G., ALONSO, A., MONROY, J., PEREZ, M., URBINA-FUENTES, M., GUEVARA, S.J., CEDENO, E., BARRIOS, R., FERMAN, J.J., MEDINA, L.M., VELAZQUEZ, E., and PEREZ-PALACIOS, G. Introduction of cyclofem once-a-month injectable contraceptive in Mexico. Contraception 58(1): 7–12. Jul. 1998.

57. GATRAD, A.R. and SHEIKH, A. Hajj: Journey of a lifetime. British Medical Journal 330(7483): 133–137. Jan. 2005.

58. GENTILE, G.P., KAUFMAN, S.C., and HELBIG, D.W. Is there any evidence for a post-tubal sterilization syndrome? Fertility and Sterility 69(2): 179–186. Feb. 1998.

59. GLASIER, A.F., SMITH, K.B., VAN DER SPUY, Z.M., HO, P.C., and CHENG, L. Amenorrhea associated with contraception: An international study on acceptability. Contraception 67(1): 1–8. Jan. 2003.

60. GOH, T.H., HARIHARAN, M., and TAN, C.H. A longitudinal study of serum iron indices and haemoglobin concentration following copper-IUD insertion. Contraception 22(4): 389–395. Oct. 1980.

61. GRUBB, G.S., MOORE, D., and ANDERSON, N.G. Pre-introductory clinical trials of Norplant implants: A comparison of seventeen countries' experience. Contraception 52(5): 287–296. Nov. 1995.

62. GUPTA, A.K. and VATSAYAN, A. Age at menarche, menstrual knowledge and practices in the apple belt of Shimla Hills. Journal of Obstetrics and Gynaecology 16(6): 548–554. Nov. 1996.

63. HALPERN, V., GRIMES, D.A., LOPEZ, L., and GALLO, M.F. Strategies to improve adherence and acceptability of hormonal methods for contraception (Cochrane Review). Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004317.

64. HARLOW, S.D. and CAMPBELL, O.M. Menstrual dysfunction: A missed opportunity for improving reproductive health in developing countries. Reproductive Health Matters 8(15): 142–147. May 2000.

65. HARLOW, S.D. and CAMPBELL, O.M. Epidemiology of menstrual disorders in developing countries: A systematic review. British Journal of Obstetrics and Gynaecology 111(1): 6–16. Jan. 2004.

66. HASSAN, E.O., EL-NAHAL, N., and EL-HUSSINIE, M. Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects. Contraception 60(2): 87–92. Aug. 1999.

67. HATCHER, R.A. and NAMNOUM, A.B. The menstrual cycle. In: Hatcher, R.A., Trussell, J., Nelson, A.L., Stewart, F.H., Cates Jr., W., Guest, F., and Kowal, D. Contraceptive Technology. 18th ed. New York, Ardent Media, Oct. 2004. p. 63–72.

68. HOSKINS, A. Pregnancy and fasting during Ramadan [letter]. British Medical Journal 304(6836): 1247. May 9, 1992.

69. HOWARD, G., BLAIR, M., DAVIS, H., and TREACY, M. The effect of norethisterone oenanthate on the full blood count. British Journal of Family Planning 8(4): 125–129. Jan. 1983.

70. HOWARD, G., BLAIR, M., FOTHERBY, K., ELDER, M.G., and BYE, P. Seven years clinical experience of the injectable contraceptive norethisterone oenanthate. British Journal of Family Planning 11(1): 9–16. Apr. 1985.

71. HUBACHER, D., GOCO, N., GONZALEZ, B., and TAYLOR, D. Factors affecting continuation rates of DMPA. Contraception 60(6): 345–351. Dec. 1999.

72. HUBER, J. and WALCH, K. Treating acne with oral contraceptives: Use of lower doses Contraception 73(1): 23–29. Jan. 2006.

73. IRVINE, G.A., CAMPBELL-BROWN, M.B., LUMSDEN, M.A., HEIKKILÄ, A., WALKER, J.J., and CAMERON, I.T. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology 105(6): 592–598. Jun. 1998.

74. IYER, V., FARQUHAR, C., and JEPSON, R. Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 1997, Issue 2. Art. No.: CD000154.

75. JABBOUR, H.N., KELLY, R.W., FRASER, H.M., and CRITCHLEY, H.O. Endocrine regulation of menstruation. Endocrine Reviews 27(1): 17–46. Feb. 2006.

76. JAHANFAR, S., GHODSY, Z., SHAHPOORIAN, F., and JAMSHIDI, R. Community-based distribution and contraception usage in Iran. Journal of Family Planning and Reproductive Health Care 31(3): 194–197. Jul. 2005.

77. JENSEN, J.T. and SPEROFF, L. Health benefits of oral contraceptives. Obstetrics and Gynecology Clinics of North America 27(4): 705–721. Dec. 2000.

78. KATZ, K. and NARE, C. Reproductive health knowledge and use of services among young adults in Dakar, Senegal. Journal of Biosocial Science 34(2): 215–231. Apr. 2002.

79. KAUNITZ, A.M. Injectable long-acting contraceptives. Clinical Obstetrics and Gynecology 44(1): 73–91. Mar. 2001.

80. KHAN, M.A. Side effects and oral contraceptive discontinuation in rural Bangladesh. Contraception 64(3): 161–167. Sep. 2001.

81. KHANNA, A., BHAWSAR, G., and BHAWSAR, R. Menstrual practices and reproductive problems: A study of adolescent girls in Rajasthan. Journal of Health Management 7(1): 91–107 Jan.–Jun. 2005.

82. KILBOURN, C.L. and RICHARDS, C.S. Abnormal uterine bleeding. Diagnostic considerations, management options. Postgraduate Medicine 109(1): 137–138, 141–144, 147–150. Jan. 2001.

83. KOETSAWANG, S. Once-a-month injectable contraceptives: Efficacy and reasons for discontinuation. Contraception 49(4): 387–398. Apr. 1994.

84. KOWALCEK, I., ROTTE, D., BANZ, C., and DIEDRICH, K. Women's attitude and perceptions towards menopause in different cultures. Cross-cultural and intra-cultural comparison of pre-menopausal and post-menopausal women in Germany and in Papua New Guinea. Maturitas 51(3): 227–235. Jul. 16, 2005.

85. LEI, Z.W., WU, S.C., GARCEAU, R.J., JIANG, S., YANG, Q.Z., WANG, W.L., and VANDER MEULEN, T.C. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception. Contraception 53(6): 357–361. Jun. 1996.

86. LUUKKAINEN, T., ALLONEN, H., HAUKKAMAA, M., LAHTEENMAKI, P., NILSSON, C.G., and TOIVONEN, J. Five years' experience with levonorgestrel-releasing IUDs. Contraception 33(2): 139–148. Feb. 1986.

87. MACGREGOR, E.A. Menstruation, sex hormones, and migraine. Neurologic Clinics 15(1): 125–141. Feb. 1997.

88. MARTINEZ, G.H., CASTANEDA, A., and CORREA, J.E. Vaginal bleeding patterns in users of Perlutal, a once-a-month injectable contraceptive consisting of 10 mg estradiol enanthate combined with 150 mg dihydroxyprogesterone acetophenide. A trial of 5462 woman-months. Contraception 58(1): 21–27. Jul. 1998.

89. MBIZVO, M.T., KASULE, J., GUPTA, V., RUSAKANIKO, S., KINOTI, S.N., MPANJU-SHUMBUSHU, W., SEBINA-ZZIWA, A.J., MWATEBA, R., and PADAYACHY, J. Effects of a randomized health education intervention on aspects of reproductive health knowledge and reported behaviour among adolescents in Zimbabwe. Social Science and Medicine 44(5): 573–577. Mar. 1997.

90. MCLAURIN, V.L., DUNSON, T.R., and DUNSON, B.A. A comparative study of 35 mcg and 50 mcg combined oral contraceptives: Results from a multicenter clinical trial. Contraception 44(5): 489–503. Nov. 1991.

91. MCMASTER, J., CORMIE, K., and PITTS, M. Menstrual and premenstrual experiences of women in a developing country. Health Care for Women International 18(6): 533–541. Nov./Dec. 1997.

92. MILSOM, I., SUNDELL, G., and ANDERSCH, B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 42(5): 497–506. Nov. 1990.

93. MOAWED, S. Indigenous practices of Saudi girls in Riyadh during their menstrual period. Eastern Mediterranean Health Journal 7(1–2): 197–203. Jan.–Mar. 2001.

94. MURPHY, E. and STEELE, C. Client-provider interactions in family planning services: Guidance from research and program experience. 2000. (MAQ Paper Vol. 1, No. 2) 12p. (Available: http://www.maqweb.org/maqdoc/vol2.pdf)

95. MURTHY, L. Communicating sexual health information to rural teenagers in Rajasthan, India. Taking Charge, Inverness, United Kingdom, Jun. 2003.

96. NARAYAN, K.A., SRINIVASA, D.K., PELTO, P.J., and VEERAMMAL, S. Puberty rituals, reproductive knowledge and health of adolescent schoolgirls in south India. Asia-Pacific Population Journal 16(2): 225–238. Jun. 2001.

97. NG, T.P., TAN, N.C., and WANSAICHEONG, G.K. A prevalence study of dysmenorrhoea in female residents aged 15-54 years in Clementi Town, Singapore. Annals of the Academy of Medicine, Singapore 21(3): 323–327. May 1992.

98. NGOM, P. Stomach washing: Menstrual inducement among the Kassena-Nankana of northern Ghana. African Population Studies 15(1): 109–116. Aug. 2000.

99. NILSSON, L. and SOLVELL, L. Clinical studies on oral contraceptives: A randomized, doubleblind, crossover study of 4 different preparations (Anovlar mite, Lyndiol mite, Ovulen, and Volidan). Acta Obstetricia et Gynecologica Scandinavica 46(Supplement 8): 1–31. 1967.

100. OFFICE NATIONAL DE LA POPULATION and MACRO INTERNATIONAL INC. Chapitre 4, Planification Familiale [Chapter 4, Family Planning]. In: Enquête Démographique et de Santé Rwanda 1992 [Rwanda Demographic and Health Survey 1992]. Kigali, Rwanda and Calverton, Maryland, Office National de la Population and Macro International Inc., Feb. 1994.

101. PAKARINEN, P., TOIVONEN, J., and LUUKKAINEN, T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception 68(1): 31–34. Jul. 2003.

102. PARDTHAISONG, T. Return of fertility after use of the injectable contraceptive Depo Provera: Up-dated data analysis. Journal of Biosocial Science 16(1): 23–34. Jan. 1984.

103. PETTA, C.A., AMATYA, R., and FARR, G. Clinical evaluation of the TCu 380A IUD at six Latin American centers. Contraception 50(1): 17–25. Jul. 1994.

104. POURESLAMI, M. and OSATI-ASHTIANI, F. Assessing knowledge, attitudes, and behavior of adolescent girls in suburban districts of Tehran about dysmenorrhea and menstrual hygiene. Journal of International Women's Studies 3(2): 1–11. May 2002.

105. RAGER, K.M., FPWLER, A., and OMAR, H.A. Successful treatment of depot medroxyprogesterone acetate-related vaginal bleeding improves continuation rates in adolescents. Scientific World Journal 6: 353–355. Mar. 19, 2006.

106. RAHIMY, M.H. and RYAN, K.K. Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension): Assessment of return of ovulation after three monthly injections in surgically sterile women. Contraception 60(4): 189–200. Oct. 1999.

107. RAUDASKOSKI, T., TAPANAINEN, J., TOMAS, E., LUOTOLA, H., PEKONEN, F., RONNI-SIVULA, H., TIMONEN, H., RIPHAGEN, F., and LAATIKAINEN, T. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: Clinical, endometrial and metabolic response. British Journal of Obstetrics and Gynaecology 109(2): 136–144. Feb. 2002.

108. REINPRAYOON, D., GILMORE, C., FARR, G., and AMATYA, R. Twelve-month comparative multicenter study of the TCu 380A and ML 250 intrauterine devices in Bangkok, Thailand. Contraception 58(4): 201–206. Oct. 1998.

109. RIVERA, R., GAITAN, J.R., NAVARRO, C.L., VALLES, J., ALMONTE, H., RUIZ, R., and HERNANDEZ, A.B. Effect of the Lippes IUD on the circulating levels of hemoglobin, hematocrit, serum iron and iron binding capacity in normal women. Contraception 17(3): 195–205. Mar. 1978.

110. RIZK, D.E. and KUMAR, R.M. Congenital afibrinogenemia: Treatment of excessive menstrual bleeding with continuous oral contraceptive. American Journal of Hematology 52(3): 237–238. Jul. 1996.

111. RÖNNERDAG, M. and ODLIND, V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. Acta Obstetricia et Gynecologica Scandinavica 78(8): 716–721. Sep. 1999.

112. ROSENBERG, M.J. and WAUGH, M.S. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. American Journal of Obstetrics and Gynecology 179(3, Pt. 1): 577–582. Sep. 1998.

113. SAID, S., OMAR, K., KOETSAWANG, S., KIRIWAT, O., SRISATAYAPAN, Y., KAZI, A., AJMAL, F., WYNTER, H.H., PRETNAR-DAROVEC, A., BENITEZ, I.B., DE LA CRUZ, J., KOVACS, R.A., BUSCA, S.K., and MACHIN, P.E. A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 34(3): 223–235. Sep. 1986.

114. SALUD SEXUAL Y REPRODUCTIVA and JOHNS HOPKINS UNIVERSITY POPULATION COMMUNICATION SERVICES (JHU/PCS). Las historias de Yoni. Pablo el descuidado: La historia de un adolescente mujeriego [The stories of Yoni. A new awakening: A story of one girl who discovers a change in her body]. Carpa Lila: Decidir te hace diferente. [Lilac Tent : Decide to be different] JHU/PCS, 1998. 17 p. (Available: http://www.m-mc.org/mmc_search.php?sp=&ref_crmb=Resources&ref_id=resources&step=results&view=detail&detail_id=PL_BOL_201&adv=mat&swater=)

115. SCHLAFF, W.D., CARSON, S.A., LUCIANO, A., ROSS, D., and BERGQVIST, A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertility and Sterility 85(2): 314–325. Feb. 2006.

116. SCHRAGER, S. Abnormal uterine bleeding associated with hormonal contraception. American Family Physician 65(10): 2073–2080. May 15, 2002.

117. SEVERY, L.J., THAPA, S., ASKEW, I., and GLOR, J. Menstrual experiences and beliefs: A multicountry study of relationships with fertility and fertility regulating methods. Women and Health 20(2): 1–20. 1993.

118. SHETH, A., JAIN, U., SHARMA, S., ADATIA, A., PATANKAR, S., ANDOLSEK, L., PRETNAR-DAROVEC, A., BELSEY, M.A., HALL, P.E., PARKER, R.A., AYENI, S., PINOL, A., and LI HOI FOO, C. A randomized, double-blind study of two combined and two progestogen-only oral contraceptives. Contraception 25(3): 243–252. Mar. 1982.

119. SIVIN, I., ALVAREZ, F., DIAZ, J., DIAZ, S., EL MAHGOUB, S., COUTINHO, E., BRACHE, V., DIAZ, M.M., FAUNDES, A., PAVEZ, M., MATTOS, C.E.R., and STERN, J. Intrauterine contraception with copper and with levonorgestrel: A randomized study of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Contraception 30(5): 443–456. Nov. 1984.

120. SIVIN, I., ALVAREZ, F., MISHELL, D.R., JR., DARNEY, P., WAN, L., BRACHE, V., LACARRA, M., KLAISLE, C., and STERN, J. Contraception with two levonorgestrel rod implants. A 5-year study in the United States and Dominican Republic. Contraception 58(5): 275–282. Nov. 1998.

121. SIVIN, I., EL MAHGOUB, S., MCCARTHY, T., MISHELL, D.R., JR., SHOUPE, D., ALVAREZ, F., BRACHE, V., JIMENEZ, E., DIAZ, J., and FAUNDES, A. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the Copper T 380AG intrauterine devices: A five-year randomized study. Contraception 42(4): 361–378. Oct. 1990.

122. SIVIN, I., STERN, J., COUTINHO, E., MATTOS, C.E.R., EL MAHGOUB, S., DIAZ, S., PAVEZ, M., ALVAREZ, F., BRACHE, V., THEVENIN, F., DIAZ, J., FAUNDES, A., DIAZ, M.M., MCCARTHY, T., MISHELL, D.R., and SHOUPE, D. Prolonged intrauterine contraception: A seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the copper T380 Ag IUDs. Contraception 44(5): 473–480. Nov. 1991.

123. SIVIN, I., STERN, J., DIAZ, J., DIAZ, M.M., FAUNDES, A., EL MAHGOUB, S., DIAZ, S., PAVEZ, M., COUTINHO, E., MATTOS, C.E., MCCARTHY, T., MISHELL, D.R., SHOUPE, D., ALVAREZ, F., BRACHE, V., and JIMENEZ, E. Two years of intrauterine contraception with levonorgestrel and with copper: A randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Contraception 35(3): 245–255. Mar. 1987.

124. SIVIN, I., VIEGAS, O., CAMPODONICO, I., DIAZ, S., PAVEZ, M., WAN, L., KOETSAWANG, S., KIRIWAT, O., ANANT, M.P., HOLMA, P., EL DIN ABDALLA, K., and STERN, J. Clinical performance of a new two-rod levonorgestrel contraceptive implant: A three-year randomized study with Norplant implants as controls. Contraception 55(2): 73–80. Feb. 1997.

125. SNOW, R., GARCÍA, S., KURESHY, N., SADANA, R., SINGH, S., BECERRA-VALDIVIA, M., LANCASTER, S., MOFOKENG, M., HOFFMAN, M., and AITKEN, I. Attributes of contraceptive technology: Women's preferences in seven countries. Beyond Acceptability: Users' Perspectives On Contraception. London, Reproductive Health Matters and World Health Organization, 1997. p. 36–48. (Available: http://www.who.int/reproductive-health/publications/beyond_acceptability_users_perspectives_on_contraception/snow.en.pdf)

126. SPEROFF, L., GLASS, R.H., and KASE, N.G. Clinical gynecologic endocrinology and infertility. 5th ed. Baltimore, Williams and Wilkins, 1994.

127. SULAK, P.J., CARL J, GOPALAKRISHNAN, I., COFFEE, A., and KUEHL, T.J. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception 70(4): 281–287. Oct. 2004

128. SUVANTO-LUUKKONEN, E., SUNDSTROM, H., PENTTINEN, J., LAARA, E., PRAMILA, S., and KAUPPILA, A. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas 26(3): 211–217. Apr. 1997.

129. TAN, A., MAHDAR, E., DJAMAL, F.R., BACHTIAR, H., TULADHAR, J., and HOESNI, R.H. Improvements in knowledge of Norplant implants acceptors: An intervention study in West Sumatra and West Java, Indonesia. Final report. Bandung, Indonesia, Padjadjaran University, Study Group on Biomedical and Human Reproduction, Jun. 1995. 41 p.

130. TANG, G.W. and LO, S.S. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: Efficacy versus acceptability. Contraception 51(4): 231–235. Apr. 1995.

131. TASK FORCE FOR EPIDEMIOLOGICAL RESEARCH ON REPRODUCTIVE HEALTH, UNITED NATIONS DEVELOPMENT PROGRAMME/UNITED NATIONS POPULATION FUND/WORLD HEALTH ORGANIZATION/WORLD BANK SPECIAL PROGRAMME OF RESEARCH DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Effects of contraceptives on hemoglobin and ferritin. Contraception 58(5): 262–273. World Health Organization. Nov. 1998.

132. THOMAS, S.L. and ELLERTSON, C. Nuisance or natural and healthy: Should monthly menstruation be optional for women? Lancet 355(9207): 922–924. Mar. 11, 2000.

133. TOLLEY, E., LOZA, S., KAFAFI, L., and CUMMINGS, S. The impact of menstrual side effects on contraceptive discontinuation: Findings from a longitudinal study in Cairo, Egypt. International Family Planning Perspectives 31(1): 15–23. Mar. 2005.

134. UNITED NATIONS POPULATION FUND—INDIA. Expanding contraceptive options: Experiences of users and providers with progestin-only injectable contraceptive-DMPA: Findings of a multi-centric study. Oct. 2004. 44 p.

135. UPADHYAY, U.D. New contraceptive choices. Population Reports Series M, No.19. Baltimore, Johns Hopkins Bloomberg School of Public Health, The INFO Project. Apr. 2005. (Available at: http://www.infoforhealth.org/pr/m19/ )

136. USKUL, A.K. Women's menarche stories from a multicultural sample. Social Science and Medicine 59(4): 667–679. Aug. 2004.

137. VARMA, H. (Thought Shop Foundation) [Educational resources (BCC Materials) for menstruation] Personal communication, Apr. 11, 2006.

138. VARMA, R., SINHA, D., and GUPTA, J.K. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) — A systematic enquiry and overview. European Journal of Obstetrics and Gynecology and Reproductive Biology 125(1): 9–28. Mar. 2006.

139. VERCELLINI, P., DE GIORGI, O., OLDANI, S., CORTESI, I., PANAZZA, S., and CROSIGNANI, P.G. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. American Journal of Obstetrics and Gynecology 175(2): 396–401. Aug. 1996.

140. VERCELLINI, P., FRONTINO, G., DE GIORGI, O., PIETROPAOLO, G., PASIN, R., and CROSIGNANI, P.G. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertility and Sterility 80(3): 560–563. Sep. 2003.

141. VESSEY, M., PAINTER, R., and MANT, J. Oral contraception and other factors in relation to hospital referral for menstrual problems without known underlying cause: Findings in a large cohort study. British Journal of Family Planning 22(4): 166–169. Jan. 1997.

142. VRBIKOVA, J. and CIBULA, D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Human Reproduction Update 11(3): 277–291. May-Jun. 2005.

143. WALRAVEN, G. Menstrual disorders in rural Gambia. Studies in Family Planning 33(3): 261–268. Sep. 2002.

144. WIEGRATZ, I. and KUHL, H. Long-cycle treatment with oral contraceptives. Drugs 64(21): 2447-2462. 2004.

145. WINKEL, C.A. Evaluation and management of women with endometriosis. Obstetrics and Gynecology 102(2): 397–408. Aug. 2003.

146. WOLLTER-SVENSSON, L.O., STADBERG, E., ANDERSSON, K., MATTSSON, L.A., ODLIND, V., and PERSSON, I. Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstetricia et Gynecologica Scandinavica 76(5): 449–454. May 1997.

147. WORLD HEALTH ORGANIZATION (WHO). Facts about once-a-month injectable contraceptives: Memorandum from a WHO meeting. Bulletin of the World Health Organization 71(6): 677–689. 1993.

148. WORLD HEALTH ORGANIZATION (WHO). Research on the menopause in the 1990s: Report of a WHO scientific group. Geneva, WHO Scientific Group on Research on the Menopause in the 1990s, 1996. (WHO Technical Report Series 866) 116 p. (Available: http://whqlibdoc.who.int/trs/WHO_TRS_866.pdf)

149. WORLD HEALTH ORGANIZATION (WHO). Iron deficiency anaemia: Assessment, prevention, and control: A guide for programme managers. Geneva, WHO, 2001. 132 p.

150. WORLD HEALTH ORGANIZATION (WHO) and JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH CENTER FOR COMMUNICATION PROGRAMS. INFORMATION AND KNOWLEDGE FOR OPTIMAL HEALTH (INFO). Decision-making tool for family planning clients and providers. Baltimore and Geneva, WHO and INFO, 2005. (WHO Family Planning Cornerstone) (Available: http://www.who.int/reproductive-health/family_planning/tool.html)

151. WORLD HEALTH ORGANIZATION (WHO) AND THE JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH (JHSPH) CENTER FOR COMMUNICATION PROGRAMS. Family planning: A global handbook for providers. Baltimore, JHSPH, The INFO Project, and WHO, 2006. (Forthcoming)

152. WORLD HEALTH ORGANIZATION (WHO) DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH and UNDP/UNFPA/WHO/WORLD BANK SPECIAL PROGRAMME OF RESEARCH DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Annual technical report 2003. Geneva, WHO, 2003. 255 p.

153. WORLD HEALTH ORGANIZATION (WHO) TASK FORCE ON LONG-ACTING SYSTEMIC AGENTS FOR FERTILITY REGULATION. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: I. Contraceptive efficacy and side effects. Contraception 37(1): 1–20. Jan. 1988.

154. WORLD HEALTH ORGANIZATION (WHO) TASK FORCE ON PSYCHOSOCIAL RESEARCH IN FAMILY PLANNING. A cross-cultural study of menstruation: Implications for contraceptive development and use. Studies in Family Planning 12(1): 3–16. Jan. 1981.

155. WORLD HEALTH ORGANIZATION (WHO). DEPARTMENT OF REPRODUCTIVE HEALTH AND RESEARCH. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva, WHO, 2004. 168 p.

156. WORLD HEALTH ORGANIZATION. SPECIAL PROGRAMME OF RESEARCH DEVELOPMENT AND RESEARCH TRAINING IN HUMAN REPRODUCTION. Long-term reversible contraception: Twelve years of experience with the TCu380A and TCu220C. Contraception 56(6): 341–352. Dec. 1997.

157. WYETH. Wyeth discusses R&D strategy and details robust pipeline at investor conference. Jun. 2, 2004. (Available: http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressreleases/2004/1145645685195.html)

158. YAHYA, S. and REHAN, N. Perceptions of menopause among rural women of Lahore. Journal of the College of Physicians and Surgeons-Pakistan 13(5): 252–254. May 2003.

159. YEUNG, D.Y.L. Psychosocial and cultural factors influencing expectations of menarche. A study on Chinese premenarcheal teenage girls. Journal of Adolescent Research 20(1): 118–134. Jan. 2005.

160. YLANEN, K., LAATIKAINEN, T., LAHTEENMAKI, P., and MOO-YOUNG, A.J. Subdermal progestin implant (Nestorone) in the treatment of endometriosis: Clinical response to various doses. Acta Obstetricia et Gynecologica Scandinavica 82(2): 167–172. Feb. 2003.

161. ZHENG, S.R., ZHENG, H.M., QIAN, S.Z., SANG, G.W., and KAPER, R.F. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 60(1): 1–8. Jul. 1999.